Low nigrostriatal reserve for motor parkinsonism in nonhuman primates.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (nonhuman primate study)
PubMed 22836146 · doi:10.1016/j.expneurol.2012.07.008
What was done
Fifteen macaque monkeys received unilateral randomized doses of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Researchers compared blinded validated parkinsonism ratings at 2 months to in vitro striatal dopamine measures and unbiased stereologic counts of tyrosine hydroxylase-immunostained substantia nigra neurons.
What was found
Residual nigral cell counts correlated linearly with 2-month parkinsonism scores (r = -0.87, p < 0.0001). Residual striatal dopamine also correlated linearly with parkinsonism scores (r = -0.77, p = 0.016) before showing a floor effect when nigral cell loss exceeded 50%. A reduction of approximately 14% to 23% in nigral neuron counts or 14% to 37% in striatal dopamine was sufficient to produce mild parkinsonism.
Why it matters
This indicates that the nigrostriatal injury threshold required to trigger parkinsonian motor symptoms is substantially lower than the historically estimated 70% loss, suggesting earlier clinical vulnerability.
Limits
The study was conducted in a small sample of 15 nonhuman primates using an acute/subacute unilateral MPTP toxin model, which does not fully capture the progressive, bilateral pathology of human Parkinson disease. Assessments were limited to a 2-month endpoint.
Cited by
- context By the time a patient presents with clinical symptoms of Parkinson's disease, they have lost 70% to 75% of the dopamine neurons in their brainstem.